Figure 2. Comparisons of Ranibizumab, 0.5 mg and 0.3 mg, vs Sham for Non–Arterial Thromboembolic Events (ATE) End Points.

Global Cox proportional hazards regression adjusted for study and baseline risk factors. All P values for the interaction test >.13. GI indicates gastrointestinal; HR, hazard ratio; and PY, person-years.